Abnormal α-synuclein interactions with rab proteins in α-synuclein A30P transgenic mice

被引:80
|
作者
Dalfó, E
Gómez-Isla, T
Rosa, JL
Bodelón, MN
Tejedor, MC
Barrachina, M
Ambrosio, S
Ferrer, I
机构
[1] Hosp Univ Bellvitge, Serv Anat Patol, Inst Neuropatol, Hosp Llobregat, Barcelona 08907, Spain
[2] Univ Barcelona, Dept Biol Cellular & Anat Patol, Unitat Neuropatol Expt, Barcelona, Spain
[3] Univ Barcelona, Hosp Llobregat, Dept Ciencias Fisiol 2, Unitat Bioquim, Barcelona, Spain
[4] Univ Navarra, Dept Neurol, Navarra, Spain
关键词
alpha-synuclein; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); Parkinson disease; Rab3a; Rab5; Rab8; rotenone;
D O I
10.1093/jnen/63.4.302
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Mutation A30P in the a-synuclein gene is a cause of familial Parkinson disease. Transgenic mice expressing wild mouse and mutant human A30P alpha-synuclein, Tg5093 mice (Tg), show a progressive motor disorder characterized by tremor, rigidity, and dystonia, accompanied by accumulation of alpha-synuclein in the soma and neurites and by a conspicuous gliosis beginning in the hippocampal formation at the age of 7 to 8 months and spreading throughout the CNS. Impaired short-term changes in synaptic strength have also been documented in hippocampal slices from Tg mice. alpha-synuclein aggregates of approximately 34 and 70 kDa, in addition to the band of 17 kDa, corresponding to the molecular weight of a-synuclein, were recovered in the PBS-soluble fraction of brain homogenates from Tg mice but not from brain samples from age-matched wildtype littermates. MPTP-treated Tg and wildtype mice produced alpha-synuclein aggregates in the PBS-, deoxycholate-, and SDS-soluble fractions. Aggregates of alpha-synuclein, although with different molecular weights, were also observed in rotenone-treated Tg and wildtype mice. Pull-down studies with members of the Rab protein family have shown that a-synuclein from Tg mice interacts with Rab3a, Rab5, and Rab8. This binding is not due to the amount of alpha-synuclein (levels of which are higher in Tg mice) and it is not dependent on the amount of Rab protein used in the assay. Rather, alpha-synuclein interactions with Rab proteins are due to mutant (x-synuclein as demonstrated in Rab pull-down assays with recombinant of wildtype and mutant A30P human alpha-synuctein. Since Rab3a, Rab5, and Rab8 are important proteins involved in synaptic vesicle trafficking and exocytosis at the synapse, vesicle endocytosis, and trans-Golgi transport, respectively, it can be suggested that these functions are impaired in Tg mice. This rationale is consistent with previous data showing that short-term hippocampal synaptic plasticity is altered and that a.-synuclein accumulates in the cytoplasm of neurons in Tg mice.
引用
收藏
页码:302 / 313
页数:12
相关论文
共 50 条
  • [21] Differential Proteome of the Striatum from A30P α-Synuclein Transgenic Mouse Model of Parkinson's Disease
    Guo, Linna
    Duan, Jinyan
    Xiong, Yan
    Qing, Hong
    Deng, Yulin
    2013 ICME INTERNATIONAL CONFERENCE ON COMPLEX MEDICAL ENGINEERING (CME), 2013, : 674 - 677
  • [22] Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice
    Marxreiter, Franz
    Ettle, Benjamin
    May, Verena E. L.
    Esmer, Hakan
    Patrick, Christina
    Kragh, Christine Lund
    Klucken, Jochen
    Winner, Beate
    Riess, Olaf
    Winkler, Juergen
    Masliah, Eliezer
    Nuber, Silke
    NEUROBIOLOGY OF DISEASE, 2013, 59 : 38 - 51
  • [23] Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice
    Pavia-Collado, Ruben
    Coppola-Segovia, Valentin
    Miquel-Rio, Lluis
    Alarcon-Aris, Diana
    Rodriguez-Aller, Raquel
    Torres-Lopez, Maria
    Paz, Veronica
    Ruiz-Bronchal, Esther
    Campa, Leticia
    Artigas, Francesc
    Montefeltro, Andres
    Revilla, Raquel
    Bortolozzi, Analia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (06) : 1 - 20
  • [24] Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse
    Taylor, Tonya N.
    Potgieter, Dawid
    Anwar, Sabina
    Senior, Steven L.
    Janezic, Stephanie
    Threlfell, Sarah
    Ryan, Brent
    Parkkinen, Laura
    Deltheil, Thierry
    Cioroch, Milena
    Livieratos, Achilleas
    Oliver, Peter L.
    Jennings, Katie A.
    Davies, Kay E.
    Ansorge, Olaf
    Bannerman, David M.
    Cragg, Stephanie J.
    Wade-Martins, Richard
    NEUROBIOLOGY OF DISEASE, 2014, 62 : 193 - 207
  • [25] α-Synuclein A30P decreases neurodegeneration and increases synaptic vesicle release probability in CSPα-null mice
    Ruiz, R.
    Biea, I. A.
    Tabares, L.
    NEUROPHARMACOLOGY, 2014, 76 : 106 - 117
  • [26] Expression of A30P mutant α-synuclein impairs macroautphagy in PC 12 cells
    Yan, Jia-qing
    Yuan, Yu-he
    Chen, Nai-hong
    ACTA PHARMACOLOGICA SINICA, 2013, 34 : 118 - 118
  • [27] Conserved core of amyloid fibrils of wild type and A30P mutant α-synuclein
    Cho, Min-Kyu
    Kim, Hai-Young
    Fernandez, Claudio O.
    Becker, Stefan
    Zweckstetter, Markus
    PROTEIN SCIENCE, 2011, 20 (02) : 387 - 395
  • [28] Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P] alpha-synuclein transgenic mouse
    Unal-Cevik, Isin
    Gursoy-Ozdemir, Yasemin
    Yemisci, Muge
    Lule, Sevda
    Gurer, Gunfer
    Can, Alp
    Mueller, Veronica
    Kahle, Philip J.
    Dalkara, Turgay
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2011, 31 (03): : 913 - 923
  • [29] α-Synuclein and Its A30P Mutant Affect Actin Cytoskeletal Structure and Dynamics
    Sousa, Vitor L.
    Bellani, Serena
    Giannandrea, Maila
    Yousuf, Malikmohamed
    Valtorta, Flavia
    Meldolesi, Jacopo
    Chieregatti, Evelina
    MOLECULAR BIOLOGY OF THE CELL, 2009, 20 (16) : 3725 - 3739
  • [30] Conditional expression of mutant A30P alpha-synuclein in the olfactory bulb of transgenic mice: implications for early stage of Parkinson's disease
    Nuber, S.
    Petrasch-Parwez, E.
    Arias-Carrion, O.
    Kohl, Z.
    Schneider, J.
    Wurst, C.
    Kurka, N.
    Koch, L.
    Calaminus, C.
    Pichler, B.
    Fendt, M.
    Nguyen, H.
    Hoersten, Sv
    Teismann, P.
    Velavan, T. P.
    Schmidt, T.
    Boy, J.
    Schmitt, I
    Hoeglinger, G. U.
    Winkler, J.
    Riess, O.
    BRAIN PATHOLOGY, 2010, 20 : 30 - 30